Anaptysbio, Inc. (ANAB) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Anaptysbio’s revenue went from $17M in fiscal 2016 to $235M in fiscal 2025, growth of about 34.1% a year.
Net income in fiscal 2025 was -$13M, a net margin of -5.6%; the best year in this period was 2016 with -$4M.
Over the twelve months to September 30, 2026, revenue was $192M and net income $184M.
Free cash flow was $20M in fiscal 2025 and positive in 1 of the 10 years shown.
The diluted share count rose 1046% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $192M | $235M | $91M | $17M | $10M | $63M | $75M | $8M | $5M | $10M | $17M |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | $298M | $227M | $66M | -$164M | -$115M | -$57M | -$24M | -$107M | -$67M | -$29M | -$3M |
| Net income | $184M | -$13M | -$145M | -$164M | -$129M | -$58M | -$20M | -$97M | -$62M | -$30M | -$4M |
| EPS (diluted) | $5.33 | $-0.44 | $-4.92 | $-6.08 | $-4.57 | $-2.11 | $-0.73 | $-3.60 | $-2.50 | $-1.52 | $-1.62 |
| R&D | — | $136M | $164M | $132M | $89M | $98M | $80M | $99M | $56M | $29M | $15M |
| Revenue growth | — | +157.0% | +432.0% | +66.8% | −83.7% | −15.8% | +837.5% | +60.0% | −50.0% | −40.1% | −5.1% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $36M | $20M | -$135M | -$121M | -$74M | -$46M | -$14M | -$70M | -$49M | -$19M | -$9M |
| Capital spending | — | -$87000 | -$358000 | -$807000 | -$358000 | -$1M | -$569000 | -$805000 | -$1M | -$290000 | -$50000 |
| Free cash flow | — | $20M | -$136M | -$122M | -$74M | -$47M | -$15M | -$70M | -$50M | -$20M | -$9M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $3M | $69M | $456000 | $50M | $0 | $0 | — | — | $0 | $0 | $1000 |
| Stock-based pay | -$12M | $4M | $7M | $33M | $27M | $15M | — | — | — | $4M | $1M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $212M | $285M | $391M | $441M | $548M | $394M | $374M | $427M | $248M | $51M |
| Debt | — | $14112 | $16M | $18M | $19M | $21M | $342000 | $3M | $10M | $7M | $0 |
| Equity | — | $37M | $71M | $88M | $262M | $356M | $397M | $405M | $486M | $308M | -$38M |
| Total assets | — | $364M | $484M | $452M | $610M | $643M | $417M | $435M | $509M | $329M | $62M |
| Shares (diluted) | 35M | 30M | 30M | 27M | 28M | 27M | 27M | 27M | 25M | 20M | 3M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating margin | 155.6% | 96.7% | 72.5% | -958.3% | -1119.4% | -89.9% | -31.8% | -1342.9% | -1334.4% | -287.8% | -18.1% |
| Net margin | 96.3% | -5.6% | -159.1% | -953.7% | -1251.3% | -91.5% | -26.6% | -1216.7% | -1233.1% | -300.7% | -25.5% |
| FCF margin | — | 8.4% | -148.7% | -708.8% | -718.9% | -74.9% | -19.6% | -879.0% | -991.4% | -197.3% | -54.4% |
| ROIC | — | 606.7% | 75.7% | -155.2% | -32.3% | -15.0% | -6.0% | -26.3% | -13.4% | -9.2% | — |
| ROE | — | -35.6% | -204.9% | -185.7% | -49.1% | -16.2% | -5.0% | -24.0% | -12.7% | -9.8% | 11.1% |
Frequently asked questions
What is Anaptysbio’s annual revenue?
$235M in fiscal 2025 and $192M over the twelve months to September 30, 2026.
How much profit does Anaptysbio make?
Net income was -$13M in fiscal 2025 (net margin -5.6%).
Is Anaptysbio’s revenue growing?
Yes: revenue rose 157.0% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.